

Cochairs:

Andrew J. Aguirre, Dana-Farber Cancer Institute, Boston, Massachusetts
Channing J. Der, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina
David S. Hong, The University of Texas MD Anderson Cancer Center, Houston, Texas
Kevan M. Shokat, University of California, San Francisco, California

THURSDAY, MARCH 5

Registration

3-7 p.m. | Diamond Foyer 1-4

Welcome and Opening Keynote Session

6-7 p.m. | Diamond 5

Session Chair: Kevan M. Shokat, University of California, San Francisco, California

6:00-6:10	Welcome and Introduction
6:10-6:15	Introduction of Keynote Speaker
6:15-6:45	Drugging RAS: What a long, strange trip it's been Channing Der University of North Carolina at Chapel Hill, Chapel Hill, North Carolina
6:45-7:00	Discussion/Q&A

Rising Star Lecture


7-7:50 p.m. | Diamond 5

Session Chair: Kevan M. Shokat, University of California, San Francisco, California

7:00-7:05	Introduction of Keynote Speaker
7:05-7:35	Response and resistance to RAS blockade in solid tumors and beyond Sandra Misale Johns Hopkins University, Baltimore, Maryland
7:35-7:50	Discussion/Q&A

Opening Reception

7:50-9 p.m. | Diamond 1-3



FRIDAY, MARCH 6

Continental Breakfast
7-8 a.m. | Diamond 1-3

Networking Roundtables Session
7:15-8:00 a.m. | Diamond 1-3


Choosing a career path: Academia vs industry Mallika Singh	How to get a paper published Andrew Aguirre
Balancing clinical and research responsibilities David S. Hong	Collaborating with industry Channing Der
Starting your lab Chiara Ambrogio	

Plenary Session 1: RAS Biochemistry, Structure, and Mutations
8:00-10:00 a.m. | Diamond 5

Session Chair: Jessie Villanueva, The Wistar Institute, Philadelphia, Pennsylvania

- 8:00-8:05 Introduction
- 8:05-8:35 **Mechanistic insights into resistance and therapeutic opportunities**
Piro Lito
Memorial Sloan Kettering Cancer Center, New York City, New York
- 8:35-9:05 **Differential biology of KRAS splice variants**
Mark Philips
New York University Perlmutter Cancer Center, New York City, New York
- 9:05-9:15 **Identification of a RAS-GTP threshold for malignant transformation***
Sophie Krahnke
Frederick National Laboratory, Frederick, Maryland
- 9:15-9:25 **Targeting S6K2 overcomes resistance to RAS inhibition in NRAS-mutant melanoma***
Jessie Villanueva
- 9:25-10:00 Discussion/ Q&A

Break
10-10:15 a.m.



Plenary Session 2: Effector Signaling

10:15 a.m.-12:20 p.m. | Diamond 5

Session Chair: Dieter Saur, German Cancer Research Center and Technical University of Munich, Munich, Germany

- | | |
|-------------|--|
| 10:15-10:20 | Introduction |
| 10:20-10:50 | Spatiotemporal determinants of KRAS effector signaling in PDAC: from subclonal evolution to stromal-immune niches
Dieter Saur |
| 10:50-11:20 | Targeting the SHOC2-RAS interaction in RAS-mutant cancers
Zachary Hauseman
Novartis Institutes for Biomedical Research, Cambridge, Massachusetts |
| 11:20-11:30 | MEK1/2 degraders uncover kinase-independent role of MEK1/2 in CRAF stabilization and maturation*
James Duncan
Fox Chase Cancer Center, Philadelphia, Pennsylvania |
| 11:30-11:40 | Dissecting the critical ERK functions that support KRAS-driven pancreatic cancer*
Jennifer Klomp
Michigan State University, Grand Rapids, Michigan |
| 11:40-12:15 | Discussion/Q&A |

Lunch on Own


12:15-2:15 p.m.

Plenary Session 3: Colorectal Cancer: Therapeutic Challenges and Opportunities

2:15-4:15 p.m. | Diamond 5

Session Chair: Ryan Corcoran, Massachusetts General Hospital, Boston, Massachusetts

- | | |
|-----------|---|
| 2:15-2:20 | Introduction |
| 2:20-2:50 | Combination strategies to overcome adaptive and acquired resistance to RAS targeted therapy in colorectal cancer
Rona Yaeger
Memorial Sloan Kettering Cancer Center, New York City, New York |
| 2:50-3:20 | Rethinking RAS targeting in colorectal cancer: Beyond G12C through novel mechanisms and combinations
Ignacio Garrido-Laguna
Moffitt Cancer Center, Tampa, Florida |



- 3:20-3:50 **Therapeutic strategies to increase the efficacy of KRAS inhibition in colorectal cancer**
Ryan Corcoran
- 3:50-4:25 Discussion/ Q&A

Presentation of Appreciation Awards to the Conference Cochairs

4:25-4:30 p.m. | Diamond 5

Presented by: Ryan Corcoran, Massachusetts General Hospital, Boston, Massachusetts

Break

4:30-4:45 p.m.

Plenary Session 4: RAS Omics and Early Detection Advances


4:45-6:30 p.m. | Diamond 5

Session Chair: Marina Pasca di Magliano, University of Michigan, Ann Arbor, Michigan

- 4:45-4:50 Introduction
- 4:50-5:20 **3D genomic analysis reveals frequent KRAS mutations in multifocal pancreatic precancer**
Laura Wood
Johns Hopkins University, Baltimore, Maryland
- 5:20-5:50 **Oncogenic KRAS as a driver of the pancreatic cancer microenvironment**
Marina Pasca di Magliano
- 5:50-6:00 **KRAS amplification as de novo oncogenic alteration and therapeutic target in human cancers***
Mark Awad
Memorial Sloan Kettering Cancer Center, New York City, New York
- 6:00-6:10 **Comprehensive structure-function analysis reveals gain- and loss-of-function mechanisms impacting oncogenic KRAS activity***
Jason Kwon
Dana-Farber Cancer Institute, Boston, Massachusetts
- 6:10-6:45 **Discussion/Q&A**

Poster Session A / Reception

6:45-8:45 p.m. | Diamond 4



SATURDAY, MARCH 7

Continental Breakfast
 7-8 a.m. | Diamond 1-3

Networking Roundtables Session
 7:15-8 a.m. | Diamond 1-3

Choosing a career path: Academia vs industry Zachary Hauseman	How to get a paper published Mark Philips
Balancing clinical and research responsibilities Eileen O'Reilly	Collaborating with industry Mariano Barbacid Julian Downward
How to write a grant Kevin Haigis	Editor-in-House: Assistant Editor, <i>Cancer Discovery</i> Lisa Situ

Keynote Lecture Session
 8:00-8:45 a.m. | Diamond 5


Session Chair: Channing J. Der, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina

- 8:00-8:05 Introduction of Keynote Speaker
- 8:05-8:35 **Targeting the oncogenic state of RAS: Lessons from tri-complex inhibitors**
Mallika Singh
Revolution Medicines, Redwood City, California
- 8:35-8:45 Discussion/Q&A

Plenary Session 5: RAS Clinical Trials and New Therapies
 8:45-10:45 a.m. | Diamond 5

Session Chair: David S. Hong, The University of Texas MD Anderson Cancer Center, Houston, Texas

- 8:45-8:50 Introduction
- 8:50-9:20 **Landscape of RAS oncoprotein targeting in NSCLC in 2026**
Ferdinandos Skoulidis
MD Anderson Cancer Center, Houston, Texas
- 9:20-9:50 **Pancreas cancer: Genomics, RAS therapeutics, and clinical landscape**
Eileen O'Reilly
Memorial Sloan Kettering Cancer Center, New York City, New York
- 9:50-10:00 **Anti-tumor efficacy of the selective oral KRAS G12D dual ON/OFF inhibitor VS-7375 as a single agent and in combination with targeted agents***



Jonathan Pachter
Verastem Oncology, Needham, Massachusetts

10:00-10:10 **Preclinical activity of an orally bioavailable PROTAC pan-KRAS degrader versus inhibitors in mutant KRAS models***
Andrea Lopez-Arroyo
Arnivas Operations Inc, New Haven, Connecticut

10:10-10:45 Discussion/Q&A

Break

10:45-11:00 a.m.

Plenary Session 6: Combinations

11:00 a.m.-1:10 p.m. | Diamond 5

Session Chair: Karen Cichowski, Brigham and Women's Hospital, Boston, Massachusetts

11:00-11:05 Introduction

11:05-11:35 **Targeting KRAS-driven pancreatic cancer: Combination therapies**
Mariano Barbacid
Spanish National Cancer Research Center (CNIO), Madrid, Spain

11:35-12:05 **Developing combinatorial therapies for RAS-driven cancers**
Karen Cichowski

12:05-12:35 **Targeting Kras in pancreatic cancer**
David Tuveson
Cold Spring Harbor Laboratory, New York City, New York


12:35-12:45 **The RAS(ON) multi-selective inhibitor, daraxonrasib (RMC-6236), induces Receptor Tyrosine Kinase (RTK) cell surface expression on pancreatic cancer cells, providing rationale for combinations with RTK targeting agents***
Ida Aronchik
Revolution Medicines, Redwood City, California

12:45-12:55 **ERK hyperactivation-induced lethality as a therapeutic strategy in RAS-driven tumors***
Alexa C. Cannon
Novartis Biomedical Research, Cambridge, Massachusetts

12:55-1:30 Discussion/Q&A

Lunch on Own

1:30-3:15 p.m.



Plenary Session 7: Immunobiology and Immunotherapies for RAS Malignancies

3:15-5:45 p.m. | Diamond 5

Session Chair: Ron DePinho, MD Anderson Cancer Center, Houston, Texas

- 3:15-3:20 Introduction
- 3:20-3:50 **Engineering T cells for effectively targeting KRAS-driven tumors**
Philip Greenberg
Fred Hutchinson Cancer Center, Seattle, Washington
- 3:50-4:20 **Mutant KRAS-targeted vaccines for cancer treatment and interception**
Elizabeth Jaffee
Johns Hopkins University School of Medicine, Baltimore, Maryland
- 4:20-4:50 **The state of KRAS resistance**
Ron DePinho
- 4:50-5:00 **KRAS amplification creates a targetable pMHC antigen for T cell engager therapy to overcome KRAS inhibitor resistance***
Lauren Stopfer
Aethon Therapeutics, New York City, New York
- 5:00-5:10 **Kras G12C and G12D driven lung cancers differ in oncogenic potency, immunogenicity, and relapse following Kras inhibition***
Esra A. Akbay
University of Texas Southwestern Medical Center, Dallas, Texas
- 5:10-5:45 Discussion/Q&A

Break

5:45-6:00 p.m.

Special Session from the U.S. National Cancer Institute RAS Initiative

6:00-7:30 p.m. | Diamond 5

Session Chair: Frank McCormick, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California, and Frederick National Laboratory for Cancer Research, Frederick, Maryland

- 6-6:10 Introduction
- 6:10-6:30 **Mechanistic insights on RAF activation through AI-driven multiscale simulation coupled with experimental validation**
Dwight V. Nissley
Frederick National Laboratory for Cancer Research, Frederick, Maryland



- 6:30-6:50 **Allosteric regulation of SOS by RRAS2**
Andrew Stephen
Frederick National Laboratory for Cancer Research, Frederick, Maryland
- 6:50-7:10 **Structural mechanisms underlying resistance to Switch-II pocket inhibitors in KRAS**
Dhirendra Simanshu
Frederick National Laboratory for Cancer Research, Frederick, Maryland
- 7:10-7:30 Discussion / Q&A

Poster Session B / Reception

7:30–9:30 p.m. | Diamond 4

SUNDAY, MARCH 8

Continental Breakfast


7-8 a.m. | Diamond 1-3

Plenary Session 8: Resistance Mechanisms

8:00-10:00 a.m. | Diamond 5

Session Chair: Chiara Ambrogio, Molecular Biotechnology Center (MBC), University of Torino, Torino, Italy

- 8:00-8:05 Introduction
- 8:05-8:35 **Signaling plasticity in pre-clinical models of resistance to KRAS inhibitors**
Chiara Ambrogio
- 8:35-9:05 **Boosting the immune system to counter resistance to KRAS inhibitory drugs in lung cancer**
Julian Downward
The Francis Crick Institute, London, United Kingdom
- 9:05-9:15 **Dynamic kinome reprogramming and metabolic rewiring drive adaptive resistance to RAS inhibition in pancreatic cancer***
Clint A. Stalnecker
University of North Carolina at Chapel Hill, Chapel Hill, North Carolina
- 9:15-9:25 **A PP2A molecular glue overcomes RAS/MAPK inhibitor resistance in KRAS-mutant non-small cell lung cancer***



Goutham Narla
The University of Michigan, Ann Arbor, Michigan

9:25-10:00 Discussion/ Q&A

Break

10-10:15 a.m.

Plenary Session 9: Targeting NRAS, HRAS, and Rare KRAS Subtypes

10:15 a.m.-12:15 p.m. | Diamond 5

Session Chair: Martin McMahon, University of Utah Huntsman Cancer Institute, Salt Lake City, Utah

10:15-10:20 Introduction

10:20-10:50 **Targeting the palmitoylation cycle in NRAS-mutant cancers**
Kevin Shannon
University of California, San Francisco, San Francisco, California

10:50-11:20 **Factors regulating permissively of organs to oncogenic RAS**
Kevin Haigis
Dana-Farber Cancer Institute, Boston, Massachusetts

11:20-11:50 **Genetic drivers of sensitivity or resistance to RAS(ON) multi- selective inhibitors in NRAS-mutated melanoma**
Martin McMahon

11:50-12:00 **Silent KRAS mutations confer altered sensitivity to targeted KRAS inhibition***
Andrew M. Waters
University of Cincinnati, Cincinnati, Ohio

12:00-12:10 **De novo design of Ras isoform selective binders***
Jason Z. Zhang
UCLA, Los Angeles, California

12:10-12:45 Discussion/ Q&A

Closing Remarks

12:45

Andrew J. Aguirre, Dana-Farber Cancer Institute, Boston, Massachusetts